Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial

Diabetes mellitus is an independent risk factor for stroke and atrial fibrillation. Therefore, the risk/benefit profile of the oral factor Xa inhibitor edoxaban stratified by diabetes is of clinical interest.

Source: International Journal of Cardiology - January 29, 2020 Category: Cardiology Authors: Anna Plitt, Christian T. Ruff, Assen Goudev, Joao Morais, Miodrag C. Ostojic, Michael A. Grosso, Hans J. Lanz, Jeong-Gun Park, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano Source Type: research